Generic repaglinide 1mg and 2mg tablets are out of stock until early May 2021.
Limited quantities of repaglinide 500 microgram tablets remain available but are unable to support any increase in demand.
A limited quantity of Prandin (repaglinide) 500 microgram, 1mg and 2mg tablets remain available but are also unable to support any increase in demand.
Unlicensed supplies of repaglinide 1mg and 2mg tablets have been sourced.
Prescribers will need to review all affected patients and assess ongoing need for repaglinide. If ongoing treatment is required, consideration should be given to prescribing an alternative glucose lowering medication where unlicensed imports of repaglinide are not appropriate.
This alert contains further information and action for providers.
Please note that no response is required via the CAS website to this alert.